Cipla eyes entry into India's weight management market amid rising demand and global competition
Cipla
is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said.
The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25.
"Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche indications...obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated.
Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management.
US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country.
Live Events
Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events.
In the CNS segment,
Cipla
has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders.
"Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he said.
The company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added.
"Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra said.
He noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability.
"We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated.
Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
ICMR says Indians taking too much salt, launches study to address issue
Excessive salt consumption is fuelling a silent epidemic in India with people at increased risk of hypertension, stroke, heart disease, and kidney disorders, according to scientists from ICMR's National Institute of Epidemiology. The scientists have initiated a community-led salt reduction study to address the issue and are focusing on low sodium salt substitutes. Higher levels of salt consumption than recommended While the World Health Organisation (WHO) recommends less than 5 grams of salt per person per day, studies show that urban Indians consume around 9.2 grams/day, and even in rural areas it is around 5.6 grams/day - both higher than recommended. One promising tool in this effort is low-sodium salt substitutes -- blends where part of the sodium chloride is replaced with potassium or magnesium salts, Sharan Murali, a senior scientist at National Institute of Epidemiology (NIE) and principal investigator of the study, said. "Lesser sodium consumption helps reduce blood pressure and improves overall heart health, making low-sodium alternatives a meaningful switch, especially for those with hypertension," Dr Murali stated. "Just switching to low-sodium salt can lower blood pressure by 7/4 mmHg on average'a small change with a big impact," Dr Murali said. Salt consumption reduction projects To tackle the issue of high salt consumption, the NIE has launched a three-year intervention project in Punjab and Telangana, supported by the Indian Council of Medical Research (ICMR). The goal is to evaluate the effectiveness of structured salt reduction counselling, delivered by health workers at Health and Wellness Centres (HWCs), in reducing blood pressure and sodium intake among individuals with hypertension, senior scientist at NIE, Dr Ganesh Kumar, who is also a part of the study, said.. "We are currently in the first year of the project, focused on baseline assessments and field preparations," Dr Kumar said. "Counselling materials are not yet finalised; rather, we aim to co-create the intervention package with the community health workers, drawing on their experiences and incorporating their suggestions. It's not just about delivering health education - it's about listening, understanding, and building together," Dr Murali said. To ensure interventions are grounded in reality, the NIE conducted a market survey across 300 retail outlets in Chennai to assess the availability and pricing of low-sodium salt (LSS). They found that LSS was available in only 28 per cent of retail outlets. It was seen in 52 per cent of supermarkets, but a dismal 4 per cent in small grocery shops. The price of LSS averaged Rs 5.6 per 100g, more than twice the price of normal iodised salt (Rs 2.7 per 100g). These findings highlight a critical supply-demand disconnect, Dr Murali said. "The lower demand for low sodium salt might be leading to its lower availability - it's a proxy indicator of awareness and access," noted Dr. Murali. To spark a public conversation around salt reduction, the NIE has also recently launched the #PinchForAChange campaign on Twitter and LinkedIn through ICMR-NIE. Using infographics, facts, and simple messages, the campaign aims to raise awareness about hidden salt sources, promote low-sodium alternatives, and empower individuals to make heart-healthy choices. "If successful, this project could lead to the integration of sustainable dietary counselling models into the existing public health system. It can bridge the gap between knowledge and action, improve health literacy, and ultimately reduce the burden of hypertension-related diseases. "This is not just about reducing salt. It's about restoring balance in our diets, our systems, and our hearts. Together, one pinch at a time, we can create lasting change," Dr Murali added.
The Hindu
an hour ago
- The Hindu
Finsen's Nobel-winning light therapy and its role in treating skin tuberculosis
In 1903, Danish physician and scientist Niels Ryberg Finsen was awarded the Nobel Prize in Physiology or Medicine 'in recognition of his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation.' Lupus vulgaris, a skin form of tuberculosis, was once treated with ultraviolet light therapy. In the late 1800s, Finsen discovered that concentrated UV light beams could inhibit bacterial growth, and he successfully used this treatment on patients. Although light therapy was widely used for a time, it eventually gave way to antibiotics. His groundbreaking work marked one of the earliest uses of a physical force --light as a therapeutic tool, and laid the foundation for what we now call phototherapy. Personal health struggles and research Finsen's scientific journey was inseparable from his personal health struggles. Born on December 15, 1860, in Tórshavn, in the Faroe Islands, then a remote territory of the Danish Kingdom, Finsen grew up in a family of educators and administrators. As a child, he showed academic promise, but his health was often precarious. By early adulthood, he began showing signs of a debilitating illness, now believed to be Niemann–Pick disease, a rare genetic condition affecting lipid metabolism. The disease caused chronic fatigue, abdominal swelling, and progressive physical decline, eventually leaving him largely immobile. Unable to pursue a traditional clinical career due to his worsening condition, Finsen turned toward research. His own body became, in part, a source of inspiration. He noticed that exposure to sunlight offered some temporary relief from his symptoms and became curious about how light interacted with human tissue. This curiosity became a lifelong focus and would eventually transform medical treatment for a highly stigmatised disease of the time: lupus vulgaris, or cutaneous tuberculosis. In the 1890s, lupus vulgaris was one of the most persistent and disfiguring manifestations of tuberculosis, which was then a leading cause of death worldwide. The skin form of TB caused ulcerating lesions, often on the face, which led to long-term deformity, particularly in young patients. At the time, there was no reliable or humane treatment. Finsen hypothesised that light --specifically the chemical rays in the blue and ultraviolet spectrum could act directly on the bacteria and stimulate healing of the infected tissue. Working initially with filtered sunlight, Finsen designed techniques to remove the heat-producing infrared rays and concentrate the short-wavelength radiation. As his understanding deepened, he transitioned to using carbon arc lamps, which allowed for controlled, high-intensity delivery of light even in low-sunlight conditions. In 1896, with support from the Danish government and scientific community, he founded the Finsen Medical Light Institute in Copenhagen. There, with a small team of physicians and nurses, he treated more than 1,000 patients suffering from lupus vulgaris over the next few years. Phototherapy, the Nobel prize and global health impact What set Finsen's work apart was its methodological rigour and reproducibility. His technique focused light beams onto the lesions for extended periods, often hours, under precise protocols. Patients experienced significant reduction in inflammation, healing of open lesions, and most importantly an arrest in disease progression. Many were children who had exhausted all other options. His clinical success offered proof that light could be used as medicine, a revolutionary idea in a period when most therapies were either surgical or pharmacological. But Finsen's contributions were not only practical, they were conceptual breakthroughs. He was among the first to propose that external physical forces, not just chemicals or immune stimulation, could be harnessed in disease management. His ideas inspired future therapies including ultraviolet sterilisation, photodynamic therapy for certain cancers, and the now-routine phototherapy for neonatal jaundice. Despite the growing recognition, Finsen's personal health deteriorated. By the early 1900s, he was unable to walk and conducted most of his work from bed, often dictating to assistants. Yet he continued to publish, consult, and treat patients until the end of his life. His declining health added urgency and poignancy to his scientific mission, and he became a symbol of resilience in the medical and public health communities across Europe. His recognition by the Nobel Committee in 1903 was significant not just for its scientific merit but for the humanitarian impact of his work. Finsen was the third person to receive the Nobel Prize in Physiology or Medicine, following Emil von Behring and Ronald Ross. His award highlighted the growing international consensus that medicine must not only advance knowledge but reduce suffering in real and measurable ways. Tragically, Finsen's own health issues prevented him from attending the Nobel Prize ceremony. His legacy today Finsen passed away the following year, in September 1904, at the age of just 43. His work outlived him. In the decades that followed, the Finsen lamp and its modified versions were used in hospitals throughout Europe and North America. The principles he established continue to influence treatment today. Phototherapy is now a standard of care in dermatology for conditions like psoriasis, vitiligo, and eczema, and it is also used in oncology, ophthalmology and neonatology. Modern techniques such as narrowband UVB, laser therapies and blue light for acne all owe conceptual debts to Finsen. Even in infection control, ultraviolet germicidal irradiation -- now widely adopted in healthcare and public spaces -- rests on the same light-tissue interaction theories Finsen helped establish. While the World Health Organization (WHO)does not name Finsen individually, its clinical guidelines for treating neonatal jaundice recommend phototherapy as a first-line, life-saving intervention. The global adoption of this therapy, especially in low- and middle-income countries, reflects Finsen's enduring influence. Today, the Finsen Institute remains part of Copenhagen University Hospital. His former residence and laboratory have been preserved as historical landmarks. Statues and memorials in Denmark honour him not as a scientist who worked quietly, under immense personal strain, to expand the frontiers of medicine.
Economic Times
2 hours ago
- Economic Times
Cipla eyes entry into India's weight management market amid rising demand and global competition
Synopsis Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader. Agencies Representative image Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25."Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders."Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added."Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability."We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
